Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin ...

Subjects in the trial saw clearance or near-clearance of skin nodules, as measured by the Investigator’s Global Assessment score.

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP), a ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and ...

The global market for prurigo nodularis treatment has witnessed substantial growth in recent years and is projected to grow from $1.64 billion in 2024 to $1.73 billion in 2025 at a compound annual ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Prurigo Nodularis Companies are Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron ...

Prurigo nodularis is a chronic skin condition that causes hard, itchy bumps called nodules. The safety and efficacy of nemolizumab for this condition were demonstrated in two clinical trials in adults ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nemolizumab (brand name Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo ...